Clincosm LogoSign in Get a demo

Establishment and Characterization of Meningioma Patient-derived Organoids

Sponsor
Chinese University of Hong Kong (Other)
Overall Status
Recruiting
CT.gov ID
NCT04478877
Collaborator
(none)
30
Enrollment
1
Location
43.3
Anticipated Duration (Months)
0.7
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

In this study, meningioma organoids will be established from patients' tissues and the characterization of the organoid will be performed.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Aims and Hypothesis to be tested:

    The investigators hypothesized that the derived organoid should have a similar morphological and genetic mutation signatures to the patient primary tissue.

    Study period: 1 year for patient recruitment and organoid generation from patient tumor

    Study population: 30

    Study samples:

    Patient's meningioma tumor sample are collected from patients with surgical needs. Sample collected are used for organoid culture. Morphological and genetic characteristics will be compared between the patient tumor sample and the corresponding derived organoids

    Primary outcome measures:

    Whole exome sequencing data of patient tumor tissue and patients-derived organoids

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    30 participants
    Observational Model:
    Other
    Time Perspective:
    Prospective
    Official Title:
    Establishment and Characterization of Meningioma Patient-derived Organoids
    Actual Study Start Date :
    May 23, 2020
    Anticipated Primary Completion Date :
    Dec 31, 2023
    Anticipated Study Completion Date :
    Dec 31, 2023

    Outcome Measures

    Primary Outcome Measures

    1. Whole exome sequencing data [7 days]

      DNA extracted from patient tumor tissue and patients-derived organoids will be perform whole exome sequencing for genetic characterization.

    Secondary Outcome Measures

    1. Immunostaining [7 days]

      H&E staining and meningioma markers immunostaining

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    1. Adult patients (aged >18 years) with meningioma

    2. Admission into Prince Wales hospitals neurosurgical services

    3. Patients with surgical needs of meningioma removal

    Exclusion Criteria:
    1. Patients (or next-of-kin as appropriate) refuse to participate into the study

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Department of Surgery, The Chinese University of Hong Kong Hong Kong Hong Kong

    Sponsors and Collaborators

    • Chinese University of Hong Kong

    Investigators

    • Principal Investigator: George KC Wong, Chinese University of Hong Kong

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    George KC Wong, Clinical Professor, Chinese University of Hong Kong
    ClinicalTrials.gov Identifier:
    NCT04478877
    Other Study ID Numbers:
    • GWMO01
    First Posted:
    Jul 21, 2020
    Last Update Posted:
    Mar 9, 2022
    Last Verified:
    Mar 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Meningioma

    Study Results

    No Results Posted as of Mar 9, 2022